|
Bautista F, Canete A, Ramirez-Villar GL, Fernandez JM, Fuster JL, Diaz de Heredia C, Astigarraga I, Garcia-Ariza M, Rives S, Dapena JL, Marquez C, Molines A, Bermudez MDM, Gallego S, Andres MDM, Verdu-Amoros J, Hernandez C, Lopez M, Catala A, Lassaletta A, Cruz O, Ramirez M, Lendinez F, Carbone A, Gomez Sirvent J, Tallon M, Acha T, Moreno L, Fernandez-Teijeiro A; Sociedad Espanola de Hematologia y Oncologia Pediatrica (SEHOP). ECLIM-SEHOP, a new platform to set up and develop international academic clinical trials for childhood cancer and blood disorders in Spain. Clin Transl Oncol. 2019 Dec;21(12):1763-1770. doi: 10.1007/s12094-019-02221-9. Epub 2019 Oct 9. PubMed PMID: 31598904.
AÑO: 2019; IF: 2.737
|
31598904
|
Fita AM, Llinares-Riestra E, Doménech-Abellán E, Bermúdez-Cortés M, Galera-Miñarro AM, Bas-Bernal A, Fuster-Soler JL. Type III pleuropulmonary blastoma in a dicer1 germline mutation carrier: The management of residual lung cystic lesions. Pediatr Blood Cancer. 2017 Aug;64(8). doi: 10.1002/pbc.26438. Epub 2017 Jan 18. PubMed PMID: 28097783.
AÑO: 2017; IF: 2.646
|
|
Ortega-García JA, López-Hernández FA, Cárceles-Álvarez A, Fuster-Soler JL, Sotomayor DI, Ramis R. Childhood cancer in small geographical areas and proximity to air-polluting industries. Environ Res. 2017 Jul;156:63-73. doi: 10.1016/j.envres.2017.03.009. Epub 2017 Mar 19. PubMed PMID: 28319819; PubMed Central PMCID: PMC5685507.
AÑO: 2017; IF: 4.732
|
|
Forero-Castro M, Robledo C, Benito R, Abáigar M, África Martín A, Arefi M, Fuster JL, de Las Heras N, Rodríguez JN, Quintero J, Riesco S, Hermosín L, de la Fuente I, Recio I, Ribera J, Labrador J, Alonso JM, Olivier C, Sierra M, Megido M, Corchete-Sánchez LA, Ciudad Pizarro J, García JL, Ribera JM, Hernández-Rivas JM. Genome-Wide DNA Copy Number Analysis of Acute Lymphoblastic Leukemia Identifies New Genetic Markers Associated with Clinical Outcome. PLoS One. 2016 Feb 12;11(2):e0148972. doi: 10.1371/journal.pone.0148972. eCollection 2016. PubMed PMID: 26872047; PubMed Central PMCID: PMC4752220.
AÑO: 2016; IF: 2.806
|
|
Martínez-Sánchez MV, Periago A, Legaz I, Gimeno L, Mrowiec A, Montes-Barqueros NR, Campillo JA, Bolarin JM, Bernardo MV, López-Álvarez MR, González C, García-Garay MC, Muro M, Cabañas-Perianes V, Fuster JL, García-Alonso AM, Moraleda JM, Álvarez-Lopez MR, Minguela A. Overexpression of KIR inhibitory ligands (HLA-I) determines that immunosurveillance of myeloma depends on diverse and strong NK cell licensing. Oncoimmunology. 2015 Oct 29;5(4):e1093721. eCollection 2016 Apr. PubMed PMID: 27141379; PubMed Central PMCID: PMC4839374.
AÑO: 2016; IF: 7.719
|